Neurotherapeutics 14(2):321332 Lucio-Eterovic AK, Piao Y, de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
Because high-quality safety data for subcutaneous lipotropic therapy is still limited, its especially important to report any unusual or persistent symptoms to your care team and to seek prompt medical attention for severe reactions such as difficulty breathing, chest pain, or signs of an allergic reaction
Gas, loss of appetite, diarrhea, constipation
Many BPC-157 products on the market require subcutaneous injection
Long-term efficacy is even more uncertain
Growth hormone receptor modulation and its implications for obesity therapy